Is LIMN or LIXT more undervalued in 2026?

CirclFi compares Liminatus Pharma, Inc. (LIMN) and Lixte Biotechnology Holdings, I (LIXT) using 13 institutional-grade valuation models. LIMN has a Quality of Company score of 3.5/10 while LIXT scores 4.2/10.

Which is a better buy — LIMN or LIXT?

Compare intrinsic values from 13 independent models against current market prices. CirclFi also calculates Value Trap scores. This is not financial advice — conduct your own analysis.

How do LIMN and LIXT valuations compare?

LIMN at $0.18 and LIXT at $5.99 are compared across Bayesian DCF, EPV, EROIC Spread, First Chicago, Markov DDM, and 8 additional models.

LIMN vs LIXT Valuation Comparison 2026 — Intrinsic Value Analysis

LIMN

Biotechnology

Liminatus Pharma, Inc.

Quality

3.5

out of 10

Value Trap

—

Price

$0.18

Last close

Models

7/13

Active

LIXT

Biotechnology

Lixte Biotechnology Holdings, I

Quality

4.2

out of 10

Value Trap

SAFE

Price

$5.99

Last close

Models

7/13

Active

Model-by-Model Comparison

Model	Type	LIMN Fair Value	LIMN Upside	LIXT Fair Value	LIXT Upside
Bayesian DCF	Intrinsic	$0.06	-67.7%	$1.66	-72.3%
First Chicago	Scenario	$•••.••	••.•%	$•••.••	••.•%
ML-RIV	Intrinsic	$•••.••	••.•%	$•••.••	••.•%
Dynamic NAV	Asset-Based	$0.02	-87.1%	$0.71	-88.2%
PWERM	Option-Based	$•••.••	••.•%	$•••.••	••.•%
Sentiment SOTP	Hybrid	$•••.••	••.•%	$•••.••	••.•%
CUCE Ensemble	Ensemble	$•••.••	••.•%	$•••.••	••.•%

🔒

Unlock Full 13-Model Comparison

Access all valuation models for LIMN vs LIXT — including EROIC Spread, First Chicago, Markov DDM, PWERM, and 7 more.

Access Full Analysis — From $27/mo →

LIMN vs LIXT — Which Stock Is More Undervalued?

LIXT scores higher with a 4.2/10 quality rating vs LIMN's 3.5/10. Both stocks are analyzed daily using SEC EDGAR filings across 13 independent models.

Comparing Liminatus Pharma, Inc. (LIMN) and Lixte Biotechnology Holdings, I (LIXT) across 13 institutional-grade valuation models reveals how each company's intrinsic value stacks up against its market price. CirclFi's engine processes SEC EDGAR 10-K and 10-Q filings, FRED macroeconomic data, and GDELT news sentiment to generate independent fair value estimates daily.

LIMN currently trades at $0.18 with a QOC of 3.5/10, while LIXT trades at $5.99 with a QOC of 4.2/10.

Both companies are analyzed with models spanning intrinsic (Bayesian DCF, EPV), scenario-based (First Chicago), regime-switching (Markov DDM, RCMH-DCF), machine learning (ML-RIV, FTNN Topology), and ensemble methods (CUCE).